Colloid replacement in the ICU

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Colloids are fluids containing large molecular weight molecules that do not readily cross the capillary membrane. Colloid replacement is becoming increasingly more common in the equine intensive care unit. Advantages of colloid therapy include improved oncotic pressure, rapid intravascular volume replacement, and improved microvascular perfusion. Edema formation is minimized through the use of colloids, rather than crystalloids, in the volume resuscitation of hypoproteinemic animals. Available colloids include both natural (biologic) and synthetic formulations. Plasma is the most common biologic colloid utilized in horses, and offers the advantage of providing a broad range of proteins in addition to its principle colloid, albumin. These additional proteins include coagulation factors, antithrombin, and immunoglobulins. The most widely used synthetic colloid in horses is hydroxyethyl starch (hetastarch). Side effects of hetastarch include dose-dependent effects on coagulation, primarily because of decreases in factor VIII and von Willebrand factor concentrations. Other synthetic or semisynthetic colloids include pentastarch, dextrans, and a polymerized ultrapurified bovine hemoglobin product. Monitoring of patients receiving colloid therapy should include direct colloid osmometry. Indirect estimates of colloid osmotic pressure are not reliable in critically ill patients and in those receiving synthetic colloids. Total protein measurements do not account for the oncotic contribution of synthetic colloids.

Original languageEnglish (US)
Pages (from-to)130-137
Number of pages8
JournalClinical Techniques in Equine Practice
Volume2
Issue number2
DOIs
StatePublished - Jun 2003

Fingerprint

colloids
Colloids
Hydroxyethyl Starch Derivatives
Horses
coagulation
horses
Osmometry
factor VIII
therapeutics
blood coagulation factors
Proteins
Blood Coagulation Factors
Antithrombins
proteins
Osmotic Pressure
Physiologic Monitoring
dextran
Dextrans
osmotic pressure
Critical Illness

Keywords

  • Colloids
  • Equine
  • Hetastarch
  • Horses
  • Plasma
  • Volume replacement

ASJC Scopus subject areas

  • Equine

Cite this

Colloid replacement in the ICU. / Magdesian, K G.

In: Clinical Techniques in Equine Practice, Vol. 2, No. 2, 06.2003, p. 130-137.

Research output: Contribution to journalArticle

@article{9e1ace3e7ee141a7950e1c1eb1c20018,
title = "Colloid replacement in the ICU",
abstract = "Colloids are fluids containing large molecular weight molecules that do not readily cross the capillary membrane. Colloid replacement is becoming increasingly more common in the equine intensive care unit. Advantages of colloid therapy include improved oncotic pressure, rapid intravascular volume replacement, and improved microvascular perfusion. Edema formation is minimized through the use of colloids, rather than crystalloids, in the volume resuscitation of hypoproteinemic animals. Available colloids include both natural (biologic) and synthetic formulations. Plasma is the most common biologic colloid utilized in horses, and offers the advantage of providing a broad range of proteins in addition to its principle colloid, albumin. These additional proteins include coagulation factors, antithrombin, and immunoglobulins. The most widely used synthetic colloid in horses is hydroxyethyl starch (hetastarch). Side effects of hetastarch include dose-dependent effects on coagulation, primarily because of decreases in factor VIII and von Willebrand factor concentrations. Other synthetic or semisynthetic colloids include pentastarch, dextrans, and a polymerized ultrapurified bovine hemoglobin product. Monitoring of patients receiving colloid therapy should include direct colloid osmometry. Indirect estimates of colloid osmotic pressure are not reliable in critically ill patients and in those receiving synthetic colloids. Total protein measurements do not account for the oncotic contribution of synthetic colloids.",
keywords = "Colloids, Equine, Hetastarch, Horses, Plasma, Volume replacement",
author = "Magdesian, {K G}",
year = "2003",
month = "6",
doi = "10.1016/S1534-7516(03)00004-0",
language = "English (US)",
volume = "2",
pages = "130--137",
journal = "Clinical Techniques in Equine Practice",
issn = "1534-7516",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Colloid replacement in the ICU

AU - Magdesian, K G

PY - 2003/6

Y1 - 2003/6

N2 - Colloids are fluids containing large molecular weight molecules that do not readily cross the capillary membrane. Colloid replacement is becoming increasingly more common in the equine intensive care unit. Advantages of colloid therapy include improved oncotic pressure, rapid intravascular volume replacement, and improved microvascular perfusion. Edema formation is minimized through the use of colloids, rather than crystalloids, in the volume resuscitation of hypoproteinemic animals. Available colloids include both natural (biologic) and synthetic formulations. Plasma is the most common biologic colloid utilized in horses, and offers the advantage of providing a broad range of proteins in addition to its principle colloid, albumin. These additional proteins include coagulation factors, antithrombin, and immunoglobulins. The most widely used synthetic colloid in horses is hydroxyethyl starch (hetastarch). Side effects of hetastarch include dose-dependent effects on coagulation, primarily because of decreases in factor VIII and von Willebrand factor concentrations. Other synthetic or semisynthetic colloids include pentastarch, dextrans, and a polymerized ultrapurified bovine hemoglobin product. Monitoring of patients receiving colloid therapy should include direct colloid osmometry. Indirect estimates of colloid osmotic pressure are not reliable in critically ill patients and in those receiving synthetic colloids. Total protein measurements do not account for the oncotic contribution of synthetic colloids.

AB - Colloids are fluids containing large molecular weight molecules that do not readily cross the capillary membrane. Colloid replacement is becoming increasingly more common in the equine intensive care unit. Advantages of colloid therapy include improved oncotic pressure, rapid intravascular volume replacement, and improved microvascular perfusion. Edema formation is minimized through the use of colloids, rather than crystalloids, in the volume resuscitation of hypoproteinemic animals. Available colloids include both natural (biologic) and synthetic formulations. Plasma is the most common biologic colloid utilized in horses, and offers the advantage of providing a broad range of proteins in addition to its principle colloid, albumin. These additional proteins include coagulation factors, antithrombin, and immunoglobulins. The most widely used synthetic colloid in horses is hydroxyethyl starch (hetastarch). Side effects of hetastarch include dose-dependent effects on coagulation, primarily because of decreases in factor VIII and von Willebrand factor concentrations. Other synthetic or semisynthetic colloids include pentastarch, dextrans, and a polymerized ultrapurified bovine hemoglobin product. Monitoring of patients receiving colloid therapy should include direct colloid osmometry. Indirect estimates of colloid osmotic pressure are not reliable in critically ill patients and in those receiving synthetic colloids. Total protein measurements do not account for the oncotic contribution of synthetic colloids.

KW - Colloids

KW - Equine

KW - Hetastarch

KW - Horses

KW - Plasma

KW - Volume replacement

UR - http://www.scopus.com/inward/record.url?scp=23744509786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744509786&partnerID=8YFLogxK

U2 - 10.1016/S1534-7516(03)00004-0

DO - 10.1016/S1534-7516(03)00004-0

M3 - Article

AN - SCOPUS:23744509786

VL - 2

SP - 130

EP - 137

JO - Clinical Techniques in Equine Practice

JF - Clinical Techniques in Equine Practice

SN - 1534-7516

IS - 2

ER -